WallStSmart

Eli Lilly and Company (LLY)vsOption Care Health Inc (OPCH)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Eli Lilly and Company generates 1175% more annual revenue ($72.25B vs $5.67B). LLY leads profitability with a 35.0% profit margin vs 3.6%. OPCH appears more attractively valued with a PEG of 1.17. LLY earns a higher WallStSmart Score of 78/100 (B+).

LLY

Strong Buy

78

out of 100

Grade: B+

Growth: 10.0Profit: 10.0Value: 5.0Quality: 6.0
Piotroski: 6/9Altman Z: 2.06

OPCH

Buy

56

out of 100

Grade: C

Growth: 5.3Profit: 6.0Value: 6.0Quality: 5.8
Piotroski: 3/9Altman Z: 2.84
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

Intrinsic value data unavailable for LLY.

OPCHFair Value (-3.8%)

Margin of Safety

-3.8%

Fair Value

$33.39

Current Price

$20.51

$12.88 premium

UndervaluedFair: $33.39Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

LLY6 strengths · Avg: 10.0/10
Market CapQuality
$948.95B10/10

Mega-cap, among the largest globally

Return on EquityProfitability
81.0%10/10

Every $100 of equity generates 81 in profit

Profit MarginProfitability
35.0%10/10

Keeps 35 of every $100 in revenue as profit

Operating MarginProfitability
49.4%10/10

Strong operational efficiency at 49.4%

Revenue GrowthGrowth
55.5%10/10

Revenue surging 55.5% year-over-year

EPS GrowthGrowth
169.9%10/10

Earnings expanding 169.9% YoY

OPCH2 strengths · Avg: 8.0/10
P/E RatioValuation
16.2x8/10

Attractively priced relative to earnings

Price/BookValuation
2.4x8/10

Reasonable price relative to book value

Areas to Watch

LLY3 concerns · Avg: 3.0/10
P/E RatioValuation
37.7x4/10

Premium valuation, high expectations priced in

Debt/EquityHealth
1.393/10

Elevated debt levels

Price/BookValuation
32.4x2/10

Trading at 32.4x book value

OPCH4 concerns · Avg: 3.5/10
Revenue GrowthGrowth
1.3%4/10

1.3% revenue growth

EPS GrowthGrowth
3.4%4/10

3.4% earnings growth

Profit MarginProfitability
3.6%3/10

3.6% margin — thin

Piotroski F-ScoreQuality
3/93/10

Weak financial health signals

Comparative Analysis Report

WallStSmart Research

Bull Case : LLY

The strongest argument for LLY centers on Market Cap, Return on Equity, Profit Margin. Profitability is solid with margins at 35.0% and operating margin at 49.4%. Revenue growth of 55.5% demonstrates continued momentum.

Bull Case : OPCH

The strongest argument for OPCH centers on P/E Ratio, Price/Book. PEG of 1.17 suggests the stock is reasonably priced for its growth.

Bear Case : LLY

The primary concerns for LLY are P/E Ratio, Debt/Equity, Price/Book.

Bear Case : OPCH

The primary concerns for OPCH are Revenue Growth, EPS Growth, Profit Margin. Thin 3.6% margins leave little buffer for downturns.

Key Dynamics to Monitor

LLY profiles as a growth stock while OPCH is a value play — different risk/reward profiles.

OPCH carries more volatility with a beta of 0.65 — expect wider price swings.

LLY is growing revenue faster at 55.5% — sustainability is the question.

LLY generates stronger free cash flow (3.0B), providing more financial flexibility.

Bottom Line

LLY scores higher overall (78/100 vs 56/100), backed by strong 35.0% margins and 55.5% revenue growth. Both earn "Strong Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Eli Lilly and Company

HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA

Eli Lilly and Company is an American pharmaceutical company headquartered in Indianapolis, Indiana, with offices in 18 countries. Its products are sold in approximately 125 countries.

Visit Website →

Option Care Health Inc

HEALTHCARE · MEDICAL CARE FACILITIES · USA

Option Care Health, Inc. offers infusion services at home and at alternative sites in the United States. The company is headquartered in Bannockburn, Illinois.

Want to dig deeper into these stocks?